Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions
- PMID: 23565531
- PMCID: PMC3681506
- DOI: 10.18632/oncotarget.890
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions
Abstract
In 2011, The National Cancer Institute (NCI) has announced 24 provocative questions on cancer. Some of these questions have been already answered in "NCI's provocative questions on cancer: some answers to ignite discussion" (published in Oncotarget, 2011, 2: 1352.) The questions included "Why do many cancer cells die when suddenly deprived of a protein encoded by an oncogene?" "Can we extend patient survival by using approaches that keep tumors static?" "Why are some disseminated cancers cured by chemotherapy alone?" "Can we develop methods to rapidly test interventions for cancer treatment or prevention?" "Can we use our knowledge of aging to enhance prevention or treatment of cancer?" "What is the mechanism by which some drugs commonly and chronically used for other indications protect against cancer?" "How does obesity contribute to cancer risk?" I devoted a single subchapter to each the answer. As expected, the provocative questions were very diverse and numerous. Now I choose and combine, as a single problem, only three last questions, all related to common mechanisms and treatment of age-related diseases including obesity and cancer. Can we use common existing drugs for cancer prevention and treatment? Can we use some targeted "cancer-selective" agents for other diseases and … aging itself.
Similar articles
-
NCI's provocative questions on cancer: some answers to ignite discussion.Oncotarget. 2011 Dec;2(12):1352-67. doi: 10.18632/oncotarget.432. Oncotarget. 2011. PMID: 22267462 Free PMC article.
-
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857062 Review.
-
NCI-60 Cell Line Screening: A Radical Departure in its Time.J Natl Cancer Inst. 2016 Jan 11;108(5):djv388. doi: 10.1093/jnci/djv388. Print 2016 May. J Natl Cancer Inst. 2016. PMID: 26755050
-
Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information.JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad015. doi: 10.1093/jncics/pkad015. JNCI Cancer Spectr. 2023. PMID: 36929393 Free PMC article.
-
National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.Clin Pharmacol Ther. 2017 May;101(5):616-618. doi: 10.1002/cpt.585. Epub 2017 Mar 22. Clin Pharmacol Ther. 2017. PMID: 27981567 Review.
Cited by
-
Mikhail 'Misha' Blagosklonny's enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.Aging (Albany NY). 2025 Jan 12;17(1):1-15. doi: 10.18632/aging.206189. Epub 2025 Jan 12. Aging (Albany NY). 2025. PMID: 39808121 Free PMC article. Review.
-
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.Oncotarget. 2016 Jun 7;7(23):34832-44. doi: 10.18632/oncotarget.8989. Oncotarget. 2016. PMID: 27145454 Free PMC article.
-
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.Oncotarget. 2015 Mar 10;6(7):4633-48. doi: 10.18632/oncotarget.3079. Oncotarget. 2015. PMID: 25609197 Free PMC article.
-
Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women.Oncotarget. 2015 Aug 28;6(25):21100-19. doi: 10.18632/oncotarget.4228. Oncotarget. 2015. PMID: 26053184 Free PMC article.
-
Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy.Oncotarget. 2014 Jul 15;5(13):4945-58. doi: 10.18632/oncotarget.2066. Oncotarget. 2014. PMID: 24970814 Free PMC article.
References
-
- Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011;8:511–512. - PubMed
-
- Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645–2652. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials